Matthew S. Davids, MD, MMSc

Articles

Factors for Consideration in Treatment Decision-making for MCL

July 15th 2022

Focusing on the differences in treatment considerations between younger and older patients, Michael Wang, MD, discusses the current treatment landscape in mantle cell lymphoma.

Disease Overview: Mantle Cell Lymphoma

July 15th 2022

Anthony R. Mato, MD, MSCE, introduces the panel, and Alexey V. Danilov, MD, PhD, provides an overview of the incidence, presentation, pathologic features, and treatment landscape for mantle cell lymphoma.

Dr. Davids on the Future of CAR T-Cell Therapy in CLL

October 27th 2020

Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Davids on Investigational Doublets and Triplets in CLL

October 15th 2020

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

Dr. Davids on Selecting Between Continuous and Time-Limited Therapy in CLL

October 13th 2020

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

Dr. Davids on Factors to Inform Treatment Selection in CLL

October 9th 2020

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

Dr. Davids on the Use of Chemoimmunotherapy in CLL

October 6th 2020

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Dr. Davids on Remaining Questions With Umbralisib/Ibrutinib in CLL and MCL

August 10th 2020

Matthew S. Davids, MD, MMSc, discusses remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Davids on Updated Data With Ibrutinib/Umbralisib in R/R CLL and MCL

July 8th 2020

Matthew S. Davids, MD, MMSc, discusses updated findings from a phase 1/1b study which examined the combination of ibrutinib (Imbruvica) and umbralisib in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Davids on Rationale for Ibrutinib/Umbralisib Combo in R/R CLL and MCL

July 6th 2020

Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Dr. Davids on Exciting Data With Acalabrutinib in CLL

February 4th 2020

Matthew S. Davids, MD, MMSc, director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses exciting data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Dr. Davids on Cost Effectiveness of Time-Limited Therapy With Venetoclax/Obinutuzumab in CLL

December 20th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the potential cost effectiveness of a 12-month fixed duration of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) in first-line chronic lymphocytic leukemia (CLL).

Dr. Davids on the Phase II CRC043 Trial for Patients With Richter's Transformation

June 19th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of the BCL‐2 inhibitor, venetoclax (Venclexta) with dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (R-EPOCH) to treat patients with Richter

Dr. Davids on the Use of CAR T-Cell Therapy in CLL

June 18th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of CAR T-cell therapy for the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Davids Discusses Ongoing Research With Ibrutinib Plus Venetoclax in CLL

May 15th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses ongoing research with ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Dr. Davids on Frontline Challenges in CLL

March 21st 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses challenges in the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Davids Discusses Frontline Approaches in CLL

March 9th 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses frontline treatment approaches for patients with chronic lymphocytic leukemia.

Dr. Davids Discusses Findings From DUO Study in CLL

January 8th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses updated findings from the DUO study in patients with chronic lymphocytic leukemia.

Dr. Davids Discusses Duvelisib in Relapsed/Refractory CLL

June 20th 2018

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib in relapsed/refractory chronic lymphocytic leukemia.

Dr. Davids Discusses the Results of Ibrutinib Plus FCR in CLL

February 5th 2018

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses results of a study combining ibrutinib (Imbruiva) plus fludarabine-cyclophosphamide-rituximab (FCR) in patients with chronic lymphoctic leukemia (CLL).